| Bid | 8.5 |
| Market Cap | 175.43M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.93 |
| PE Ratio (ttm) | -1.48 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10.39 |
| Volume | 106,988 |
| Avg. Volume (20D) | 351,218 |
| Open | 8.92 |
| Previous Close | 8.90 |
| Day's Range | 8.63 - 8.97 |
| 52-Week Range | 6.50 - 19.84 |
| Beta | undefined |
About CYBN
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company...
Analyst Forecast
According to 3 analyst ratings, the average rating for CYBN stock is "Buy." The 12-month stock price forecast is $138, which is an increase of 1472.65% from the latest price.
2 months ago · businesswire.com
Cybin to Participate at the 2024 Milken Institute Future of Health SummitTORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental ...
2 months ago · seekingalpha.com
Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 11th - 17th, aiming to inspire discussion and provide investment ideas. AST SpaceMobile is highly volatile but has strong pote...
